Familial mesial temporal lobe epilepsy (FMTLE) is a focal epilepsy syndrome in which mesial temporal seizures occur in two or more family members and no acquired structural cause better explains the familial pattern.
Many affected people have relatively mild epilepsy with focal aware seizures and normal MRI, but more severe forms can occur.
Where FMTLE fits in the ILAE classification
The International League Against Epilepsy includes FMTLE among focal epilepsy syndromes with onset at a variable age.
Its defining clue is the combination of mesial temporal seizure semiology and familial clustering.
Typical seizure symptoms
Mesial temporal seizures can begin with déjà vu, jamais vu, rising epigastric sensations, sudden fear, unusual smells or tastes, autonomic sensations or brief experiential phenomena.
Awareness may remain intact or become impaired as the seizure spreads.
Why mild cases can be missed
A person may have only occasional déjà vu or abdominal rising sensations and never realise these are seizures.
When several relatives report similar experiences, the familial pattern can become an important diagnostic clue.
Age at onset
Onset can occur from childhood through adulthood.
This wide age range is why FMTLE is classified among variable-age epilepsy syndromes.
EEG
Interictal EEG can be normal or show temporal epileptiform abnormalities.
Repeated EEG, sleep recording or prolonged monitoring may be needed when routine EEG is unrevealing.
MRI
MRI is often normal in familial forms.
If hippocampal sclerosis is present, clinicians must consider whether the person instead fits mesial temporal lobe epilepsy with hippocampal sclerosis, which the ILAE recognises as a separate aetiology-specific syndrome.
Genetics
FMTLE is genetically heterogeneous. Unlike some monogenic epilepsy syndromes, no single gene explains most families.
Inheritance may appear autosomal dominant with incomplete penetrance in some kindreds.
Family history
A detailed family history should ask about “funny turns”, déjà vu, unexplained fear, brief confusion, unusual smells, nocturnal seizures and convulsions rather than asking only whether anyone has “epilepsy”.
Older relatives may never have received a formal diagnosis.
Treatment
Treatment follows focal epilepsy principles.
Many people respond to standard focal-seizure medicines. Drug-resistant cases require the same specialist evaluation as non-familial temporal lobe epilepsy.
Epilepsy surgery
Familial status does not automatically exclude surgery.
If a person has drug-resistant seizures with a well-localised unilateral epileptogenic zone, presurgical assessment may still identify a resective or ablative treatment option.
Memory and cognition
Mesial temporal structures are central to memory, but cognitive effects vary widely.
Some people with mild familial epilepsy have little measurable impairment, while frequent seizures, bilateral abnormalities or treatment burden may affect memory in others.
Distinguishing FMTLE from hippocampal sclerosis epilepsy
FMTLE emphasises familial clustering and a usually non-lesional phenotype.
Mesial temporal lobe epilepsy with hippocampal sclerosis is defined by a specific structural abnormality and often has a different clinical course.
Worldwide diagnosis
FMTLE is likely under-recognised in settings where family members are separated, medical records are unavailable or subtle focal aware seizures are not identified as epilepsy.
Genetic testing may be helpful in research or selected clinical settings but is not essential for diagnosis.
The central point
FMTLE is not simply “temporal lobe epilepsy that runs in families”. It is a recognised syndrome characterised by familial clustering of mesial temporal seizure semiology, often with normal MRI and relatively mild seizures.
Related reading
Temporal Lobe Epilepsy →
Hippocampal Sclerosis →
Epilepsy Surgery and Presurgical Assessment →
Sources
Medical note: déjà vu and autonomic sensations are common outside epilepsy. Diagnosis depends on recurrent stereotyped events and the wider clinical picture.
Evidence checked: September 2026.